Zacks Investment Research on MSN

Lam Research hits 52-week high: Is the stock still worth buying?

Lam Research Corporation LRCX has had a remarkable run so far this year, with its shares hitting a new 52-week high of $173.58 last Friday. The stock has been a key beneficiary of the artificial ...
Hosted on MSN

Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda

Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...